-- Cutia Therapeutics (HKG:2487) said it completed a Phase 3 clinical trial in China for its botulinum toxin type A product for treating moderate to severe glabellar lines, according to a Monday Hong Kong bourse filing.
The study met primary and secondary endpoints, with efficacy comparable to Botox and a favorable safety profile.
The pharmaceutical company said no treatment-related serious adverse events or new safety signals were observed.